AstraZeneca Targets Hetero Over Nexium ANDA

Law360, New York (August 4, 2011, 2:13 PM EDT) -- AstraZeneca AB sued Hetero Drugs Ltd. on Tuesday in New Jersey federal court, continuing a fight to protect its patents for acid reflux drug Nexium.

The plaintiff alleges that Hetero's submission of an abbreviated new drug application seeking the U.S. Food and Drug Administration's approval of its generic Nexium capsules infringes on a trio of AstraZeneca's patents.

“Hetero is aware that its [ANDA], if approved, will be used in contravention of plaintiffs’ rights" under the patents, the complaint says.

The patents-in-suit are U.S. Patent Numbers 5,714,504,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.